Savara Inc (NASDAQ:SVRA) Director David A. Ramsay acquired 40,215 shares of Savara stock in a transaction dated Tuesday, June 18th. The stock was purchased at an average price of $2.37 per share, with a total value of $95,309.55. Following the completion of the purchase, the director now owns 23,570 shares of the company’s stock, valued at $55,860.90. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
SVRA stock traded up $0.33 during trading on Wednesday, hitting $2.71. 2,067,100 shares of the company traded hands, compared to its average volume of 364,999. The company has a current ratio of 12.05, a quick ratio of 12.05 and a debt-to-equity ratio of 0.24. The stock has a market cap of $85.28 million, a P/E ratio of -2.10 and a beta of 0.95. Savara Inc has a 1 year low of $2.32 and a 1 year high of $14.06.
Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.05. On average, research analysts predict that Savara Inc will post -1.62 earnings per share for the current fiscal year.
Several research analysts have recently issued reports on the company. Zacks Investment Research cut Savara from a “buy” rating to a “hold” rating in a research note on Friday, May 17th. BidaskClub cut Savara from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 14th. JMP Securities cut Savara from an “outperform” rating to a “market perform” rating and set a $2.60 price target for the company. in a research report on Thursday, June 13th. Roth Capital set a $10.00 price target on Savara and gave the company a “hold” rating in a research report on Tuesday, May 14th. Finally, ValuEngine upgraded Savara from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. Savara currently has a consensus rating of “Hold” and an average price target of $8.10.
ILLEGAL ACTIVITY NOTICE: This article was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.tickerreport.com/banking-finance/4380016/savara-inc-nasdaqsvra-director-david-a-ramsay-purchases-40215-shares.html.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.